Researchers at North Carolina-based Locus Biosciences think they have a potential cure for antibiotic resistance using CRISPR’s lesser-known Cas3 enzyme. Most of the interest in CRISPR technology centers around the enzyme Cas9, which acts as a type of genetic scissors, allowing scientists to snip out, edit and replace DNA at certain intervals along the genome. However, Cas3 goes beyond Cas9 by targeting the DNA of bacterial cells and then chewing them up beyond the point of repair. This action turns the CRISPR-based bacterial immune system on itself, prompting the cell’s death. Co-founder Paul Garofolo likens the process to Pac-Man. “It comes in and it chews the target DNA so when a Pac-Man chews